Sotera Health Co. operates as a critical infrastructure provider within the highly regulated healthcare supply chain, specializing in end-to-end sterilization, microbiological testing, and materials validation. The company functions through three primary segments: Sterigenics, which provides outsourced terminal sterilization services using gamma irradiation, ethylene oxide (EtO), and electron beam technologies; Nelson Labs, which offers microbiological and analytical chemistry testing, shelf-life validation, and advisory services; and Nordion, a leading global supplier of Cobalt-60 isotopes and gamma irradiation systems. In 2023, the company generated approximately $1.05 billion in total revenue, with Sterigenics accounting for the majority at roughly 63.5%, followed by Nelson Labs at 21.1%, and Nordion at 15.2%.
Sotera Health's business model is characterized by high barriers to entry, recurring revenue streams, and deeply embedded customer relationships. Because its services are often written directly into a customer's regulatory filings (such as FDA approvals for medical devices or pharmaceuticals), switching providers is costly, slow, and risky for manufacturers. The company operates a global network of over 50 facilities across North America, Europe, and Asia, serving thousands of customers, including top-tier medical device and pharmaceutical companies. Its competitive position is fortified by its scale, technical expertise, and the non-discretionary, government-mandated nature of its safety and compliance services.
